BARDA (@BARDA) / X

BARDA

3,052 posts

BARDA

@BARDA

Advancing countermeasures against 21st century health threats by bringing together public private partnerships and advancing innovation. Part of HHS/ASPR.

Washington, DC

medicalcountermeasures.gov

Joined April 2017

BARDA
@BARDA
Jun 13, 2024
Through the @RRPV_Consortium and #ProjectNextGen, we’re partnering with @castlevaxbio, Cyanvac, and @Vaxart to evaluate novel #COVID19 vaccine candidates that are needle-free. Learn more: ow.ly/Z3CF50SipJ3
00:00
BARDA
@BARDA
Nov 15, 2022
Two mask designs have been awarded $150,000 each as winners of the #MaskInnovationChallenge Phase 2 from BARDA, @NIOSH, & @NIST. Read the #BARDAStory about the designs from winners @Air99_LLC & @readimask, as well as runners-up @flo_mask & @LeviStraussCo: ow.ly/sVK950LEPit
00:00
BARDA
@BARDA
Mar 30, 2020
Today, we took steps to speed the development and secure domestic manufacturing of two vaccines – one by @moderna_tx & another by @JanssenUS - to prevent the spread of #COVID19 and protect people at home and abroad. hhs.gov/about/news/202…
BARDA
@BARDA
Mar 15, 2024
Under #ProjectNextGen, we’re advancing the clinical development of next generation COVID-19 #vaccines that offer broader, longer lasting protection & that are easier to administer & reduce viral spread. This #NationalVaccinationDay, learn more: ow.ly/VAjA50QTKNZ
BARDA
@BARDA
Oct 31, 2023
The @T2Bio T2Biothreat Panel is the newest @US_FDA clearance of a BARDA-supported product. This molecular diagnostic test runs on the T2Dx instrument and detects & differentiates between 6 biothreat pathogens in a single sample. Learn more: ow.ly/7hgu50Q2nMN
BARDA
@BARDA
Jan 23, 2024
Under #ProjectNextGen, we are partnering with @Vaxart on planning a Phase 2b clinical trial that would compare its oral pill #COVID19 vaccine candidate to a currently approved COVID-19 vaccine. Learn more about Project NextGen: ow.ly/kSoq50QtHxE
BARDA
@BARDA
Jun 2, 2023
Mucosal vaccines may have the potential to help prevent infection and transmission of COVID-19. Check out the latest #BARDAResearch to learn about progress in development & remaining challenges in getting vaccines to licensure: ow.ly/SIQS50OBhf8
BARDA
@BARDA
May 1, 2023
BARDA is committed to supporting the next generation of innovative vaccine & therapeutic investments to help protect our nation against coronavirus and other infectious diseases.
BARDA
@BARDA
Apr 20, 2020
We are joining forces with Tangen Biosciences to develop a fast, accurate, point-of-care molecular diagnostic test for use on the Tangen GeneSpark molecular diagnostic system to aid in diagnosing #COVID-19.  medicalcountermeasures.gov/newsroom/2020/…
BARDA
@BARDA
Apr 16, 2020
A Bluetooth-enabled, 60-second, point-of-care #COVID19 diagnostic test that could help clinicians to more quickly and effectively diagnose patients is being developed through a partnership between BARDA and @hememics. medicalcountermeasures.gov/newsroom/2020/…
BARDA
@BARDA
May 15, 2023
We’re excited about Project NextGen which supports vaccine innovation efforts to enhance efficacy & accessibility of vaccines for future pathogens with pandemic potential – they will ideally be developed faster, easier to transport, & cost less compared to current vaccines.
BARDA
@BARDA
May 2, 2023
🆕 As a part of Project NextGen, we opened a new area of interest (AOI 15) under our Broad Agency Announcement (BAA), seeking submissions for the clinical development & efficacy of phase 2-ready next generation #COVID19 vaccines. sam.gov/opp/6f989eb9c4…
BARDA
@BARDA
Oct 4, 2022
Today, we purchased a supply of @Amgen’s Nplate, a drug to combat the effects of acute radiation sickness after radiological or nuclear emergencies. For more about how we leverage existing technology & inventory management practices to ensure preparedness: bit.ly/3EedtyT
BARDA
@BARDA
Nov 6, 2020
We’re partnering w/ @JPEOCBRND to provide subject matter expertise to @humanigen to support development of a monoclonal antibody therapeutic w/ potential to treat cytokine storm, reducing hospital stays & preventing lung damage from #COVID19. Learn more: medicalcountermeasures.gov/newsroom/2020/…